CD163 and tuberculosis: Regarding patient risk factors, for instance, it was recently demonstrated that pre-treatment levels of the inflammatory mediators interferon-gamma-induced protein 10 (IP-10) and soluble CD163 (sCD163) were associated with increased risk for DILI due to anti-tuberculosis agents and that IL-22 binding protein (IL-22BP) correlated with protection from DILI [82].